Current treatment options |
TNF-alfaremmers: adalimumab, etanercept, infliximab; Il12/23 remmer: ustekinumab; IL17 remmers: secukinumab, ixekizumab, brodalumab. |
Therapeutic value |
Possible added value |
Substantiation |
Verwacht superieur wat betreft efficacy en vergelijkbaar wat betreft safety in vergelijking met ustekinumab. |
Duration of treatment |
continuous |
Frequency of administration |
1 times every 8 weeks |
Dosage per administration |
100 mg |
References |
Langley et al, Br J Dermatol. 2017 Jun 21; Reich et al, J Am Acad Dermatol. 2017 Mar;76(3):405-417.; Zhuang et al, Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310.; Gordon et al, N Engl J Med. 2015 Jul 9;373(2):136-44.; Sofen et al, J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. |